Organon's Tofidence Biosimilar Gains FDA Approval for Expanded Use in Cancer and COVID-19
OGN has more than doubled off its 52-week low of $5.69 on light trading volume (0.2× avg).
Summary
Organon received FDA approval to expand the use of its biosimilar drug, Tofidence, for severe cytokine release syndrome in cancer patients and for COVID-19 patients requiring breathing support. This regulatory win broadens the market for Tofidence, which is a biosimilar to Roche's Actemra. However, the company is currently under a definitive merger agreement to be acquired by Sun Pharmaceutical for $14.00 per share, which limits the immediate upside impact of this positive news on Organon's stock price.
At the time of this announcement, OGN was trading at $13.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $5.69 to $13.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.